1372540-91-4

Basic information

• Product Name: 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid 2-amino-2-(hydroxymethyl)-1,3-propanediol salt
• Synonyms: 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid 2-amino-2-(hydroxymethyl)-1,3-propanediol salt
• CAS NO: 1372540-91-4
• Molecular Weight: 554.566
• Mol File: 1372540-91-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid 2-amino-2-(hydroxymethyl)-1,3-propanediol salt(CAS DataBase Reference)
• NIST Chemistry Reference: 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid 2-amino-2-(hydroxymethyl)-1,3-propanediol salt(1372540-91-4)
• EPA Substance Registry System: 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid 2-amino-2-(hydroxymethyl)-1,3-propanediol salt(1372540-91-4)

Safety Data

• Hazardous Substances Data: 1372540-91-4(Hazardous Substances Data)

Upstream product

• 1372540-21-0 methyl 2-methyl-5-(4-morpholinyl)-1H-benzimidazole-7-carboxylate 
• 1372540-24-3 methyl 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylate 
• 1203486-58-1 methyl 3-amino-5-(4-morpholinyl)-2-nitrobenzoate 
• 874301-23-2 3-amino-5-chloro-2-nitrobenzoic acid methyl ester 
• 2516-95-2 5-chloro-2-nitrobenzoic acid 
• 1372540-25-4 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(morpholin-4-yl)-1H-1,3-benzodiazole-4-carboxylic acid 
• 77-86-1 2-amino-2-hydroxymethyl-1,3-propanediol 

Relevant articles and documents

COMBINATION DRUG THERAPY

A novel combination comprising the androgen receptor inhibitor, 4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide or a pharmaceutically acceptable salt or solvate thereof, with a PI3K? inhibitor, 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of androgen receptor and/or PI3K? is beneficial, e.g., cancer.